α-Synuclein expression selectively affects tumorigenesis in mice modeling Parkinson's disease

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Israeli, Eitan ^a,b   Yakunin, Eugenia ^a   Zarbiv, Yonaton ^a   Hacohen Solovich, Amir ^a   Kisos, Haya ^a   Loeb, Virginie ^a   Lichtenstein, Michal ^a   Ben Gedalya, Tziona ^a   Sabag, Ofra ^a   Pikarsky, Eli ^a   Lorberboum Galski, Haya ^a   Sharon, Ronit ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN;

AGE; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST ADENOCARCINOMA; CARCINOGENESIS; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; LEWIS CARCINOMA; MELANOMA B16; MOUSE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; TRANSGENIC MOUSE; TUMOR CELL; TUMOR GROWTH; ANIMAL; C57BL MOUSE; DISEASE MODEL; EXPERIMENTAL MELANOMA; FEMALE; HUMAN; MALE; METABOLISM; PATHOLOGY; PRECANCER; TUMOR CELL LINE;

MUS; MUS MUSCULUS;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; ANIMALS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PARKINSON DISEASE; PRECANCEROUS CONDITIONS;

EID: 79956214024     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019622     Document Type: Article

References (66)

1. Fahn S, Sulzer D, (2004) Neurodegeneration and neuroprotection in Parkinson disease. Neuro Rx 1: 139-154.
2. Poewe W, (2007) Dysautonomia and cognitive dysfunction in Parkinson's disease. Mov Disord 22 (Suppl 17): S374-378.
3. Cookson MR, van der Brug M, (2008) Cell systems and the toxic mechanism(s) of alpha-synuclein. Exp Neurol 209: 5-11.
4. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K, (2004) Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318: 121-134.
5. Lee VM, Trojanowski JQ, (2006) Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron 52: 33-38.
6. Moore DJ, West AB, Dawson VL, Dawson TM, (2005) Molecular pathophysiology of Parkinson's disease. Ann Rev Neurosci 28: 57-87.
7. Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A, (2006) Genetics of Parkinson's disease and parkinsonism. Ann Neurol 60: 389-398.
8. Duda JE, Lee VM, Trojanowski JQ, (2000) Neuropathology of synuclein aggregates. J Neurosci Res 61: 121-127.
9. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, et al. (1997) Alpha-synuclein in Lewy bodies. Nature 388: 839-840.
10. Goedert M, (2001) Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2: 492-501.
11. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, et al. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302: 841.
12. Gitler AD, Bevis BJ, Shorter J, Strathearn KE, Hamamichi S, et al. (2008) The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc Natl Acad Sci U S A 105: 145-150.
13. Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, et al. (2006) Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313: 324-328.
14. Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC, (2005) Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123: 383-396.
15. Chandra S, Fornai F, Kwon HB, Yazdani U, Atasoy D, et al. (2004) Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. Proc Natl Acad Sci U S A 101: 14966-14971.
16. Larsen KE, Schmitz Y, Troyer MD, Mosharov E, Dietrich P, et al. (2006) {alpha}-Synuclein Overexpression in PC12 and Chromaffin Cells Impairs Catecholamine Release by Interfering with a Late Step in Exocytosis. J Neurosci 26: 11915-11922.
17. Ben Gedalya T, Loeb V, Israeli E, Altschuler Y, Selkoe DJ, et al. (2009) Alpha-synuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recycling. Traffic 10: 218-234.
18. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, et al. (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65: 66-79.
19. Murphy DD, Rueter SM, Trojanowski JQ, Lee VM, (2000) Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 20: 3214-3220.
20. Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, et al. (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci 22: 8797-8807.
21. El-Agnaf OM, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, et al. (2003) Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. Faseb J 17: 1945-1947.
22. Barbour R, Kling K, Anderson JP, Banducci K, Cole T, et al. (2008) Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis 5: 55-59.
23. Hoepken HH, Gispert S, Azizov M, Klinkenberg M, Ricciardi F, et al. (2008) Parkinson patient fibroblasts show increased alpha-synuclein expression. Exp Neurol 212: 307-313.
24. Kawashima M, Suzuki SO, Doh-ura K, Iwaki T, (2000) alpha-Synuclein is expressed in a variety of brain tumors showing neuronal differentiation. Acta Neuropathol 99: 154-160.
25. Fung KM, Rorke LB, Giasson B, Lee VM, Trojanowski JQ, (2003) Expression of alpha-, beta-, and gamma-synuclein in glial tumors and medulloblastomas. Acta Neuropathol (Berl) 106: 167-175.
26. Bruening W, Giasson BI, Klein-Szanto AJ, Lee VM, Trojanowski JQ, et al. (2000) Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. Cancer 88: 2154-2163.
27. Ye Q, Wang TF, Peng YF, Xie J, Feng B, et al. (2010) Expression of alpha-, beta- and gamma-synuclein in colorectal cancer, and potential clinical significance in progression of the disease. Oncol Rep 23: 429-436.
28. Matsuo Y, Kamitani T, (2010) Parkinson's disease-related protein, alpha-synuclein, in malignant melanoma. PLoS One 5: e10481.
29. Staropoli JF, (2008) Tumorigenesis and neurodegeneration: two sides of the same coin? Bioessays 30: 719-727.
30. Morris LG, Veeriah S, Chan TA, (2010) Genetic determinants at the interface of cancer and neurodegenerative disease. Oncogene 29: 3453-3464.
31. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, et al. (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34: 521-533.
32. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, et al. (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13: 159-170.
33. Specht CG, Schoepfer R, (2001) Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice. BMC Neurosci 2: 11.
34. Jankowsky JL, Xu G, Fromholt D, Gonzales V, Borchelt DR, (2003) Environmental enrichment exacerbates amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J Neuropathol Exp Neurol 62: 1220-1227.
35. Irony-Tur-Sinai M, Lichtenstein M, Brenner T, Lorberboum-Galski H, (2009) IL2-caspase3 chimeric protein controls lymphocyte reactivity by targeted apoptosis, leading to amelioration of experimental autoimmune encephalomyelitis. Int Immunopharmacol 9: 1236-1243.
36. Eisenbach L, Segal S, Feldman M, (1983) MHC imbalance and metastatic spread in Lewis lung carcinoma clones. Int J Cancer 32: 113-120.
37. Assayag K, Yakunin E, Loeb V, Selkoe DJ, Sharon R, (2007) Polyunsaturated Fatty Acids Induce {alpha}-Synuclein-Related Pathogenic Changes in Neuronal Cells. Am J Pathol 171: 2000-2011.
38. Israeli E, Sharon R, (2009) Beta-synuclein occurs in vivo in lipid-associated oligomers and forms hetero-oligomers with alpha-synuclein. J Neurochem 108: 465-474.
39. Haass C, Lemere CA, Capell A, Citron M, Seubert P, et al. (1995) The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nat Med 1: 1291-1296.
40. Loeb V, Yakunin E, Saada A, Sharon R, (2010) The transgenic over expression of {alpha}-Synuclein and not its related pathology, associates with complex I inhibition. J Biol Chem 285: 7334-7343.
41. Bystryn JC, (1976) Release of tumor-associated antigens by murine melanoma cells. J Immunol 116: 1302-1305.
42. Horiuchi M, Yamazaki N, Ikeda T, Ishiguro N, Shinagawa M, (1995) A cellular form of prion protein (PrPC) exists in many non-neuronal tissues of sheep. J Gen Virol 76 (Pt 10): 2583-2587.
43. Lee HJ, Patel S, Lee SJ, (2005) Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci 25: 6016-6024.
44. Lee PH, Lee G, Park HJ, Bang OY, Joo IS, et al. (2006) The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J Neural Transm 113: 1435-1439.
45. Borghi R, Marchese R, Negro A, Marinelli L, Forloni G, et al. (2000) Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett 287: 65-67.
46. Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, et al. (2011) Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75: 1766-1772.
47. Inzelberg R, J. J, (2007) Are Parkinson disease patients protected from some but not all cancers? neurology 69: 1542-1550.
48. D'Amelio M, Ragonese P, Sconzo G, Aridon P, Savettieri G, (2009) Parkinson's disease and cancer: insights for pathogenesis from epidemiology. Ann N Y Acad Sci 1155: 324-334.
49. Bajaj A, Driver JA, Schernhammer ES, (2010) Parkinson's disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control 21: 697-707.
50. Zanetti R, Rosso S, Loria DI, (2007) Parkinson's disease and cancer. Cancer Epidemiol Biomarkers Prev 16: 1081.
51. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.
52. Yang Y, Geldmacher DS, Herrup K, (2001) DNA replication precedes neuronal cell death in Alzheimer's disease. J Neurosci 21: 2661-2668.
53. Gupta A, Dawson VL, Dawson TM, (2008) What causes cell death in Parkinson's disease? Ann Neurol 64 (Suppl 2): S3-15.
54. Garber K, (2010) Parkinson's disease and cancer: the unexplored connection. J Natl Cancer Inst 102: 371-374.
55. Dawson TM, Dawson VL, (2010) The role of parkin in familial and sporadic Parkinson's disease. Mov Disord 25 (Suppl 1): S32-39.
56. Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, et al. (2010) Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet 42: 77-82.
57. Garber K, Parkinson's disease and cancer: the unexplored connection. J Natl Cancer Inst 102: 371-374.
58. Poulogiannis G, McIntyre RE, Dimitriadi M, Apps JR, Wilson CH, et al. (2010) PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc Natl Acad Sci U S A.
59. Tay SP, Yeo CW, Chai C, Chua PJ, Tan HM, et al. (2010) Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells. J Biol Chem.
60. Staropoli JF, McDermott C, Martinat C, Schulman B, Demireva E, et al. (2003) Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 37: 735-749.
61. Fan Y, Limprasert P, Murray IV, Smith AC, Lee VM, et al. (2006) Beta-synuclein modulates alpha-synuclein neurotoxicity by reducing alpha-synuclein protein expression. Hum Mol Genet 15: 3002-3011.
62. Ohtake H, Limprasert P, Fan Y, Onodera O, Kakita A, et al. (2004) Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology 63: 805-811.
63. Fujita M, Sugama S, Sekiyama K, Sekigawa A, Tsukui T, et al. (2010) A beta-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain. Nat Commun 1: 110.
64. Ahmad M, Attoub S, Singh MN, Martin FL, El-Agnaf OM, (2007) Gamma-synuclein and the progression of cancer. Faseb J 21: 3419-3430.
65. Ji H, Liu YE, Jia T, Wang M, Liu J, et al. (1997) Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res 57: 759-764.
66. Morgan J, Hoekstra AV, Chapman-Davis E, Hardt JL, Kim JJ, et al. (2009) Synuclein-gamma (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma. Gynecol Oncol 114: 293-298.